Literature DB >> 16690936

A new subtype of hepatitis C virus genotype 1: complete genome and phylogenetic relationships of an Equatorial Guinea isolate.

Maria Alma Bracho1, Francy Yolima Carrillo-Cruz, Enrique Ortega, Andrés Moya, Fernando González-Candelas.   

Abstract

Hepatitis C virus (HCV) is the leading cause of chronic liver disease and is associated with hepatocellular carcinoma. However, there have been few studies on the distribution and genetic diversity of HCV isolates in non-developed countries. Here, the complete genome sequence of an HCV genotype 1 isolate from Equatorial Guinea is reported, the first complete HCV-1 genome of African origin. Phylogenetic analysis revealed that this sequence always grouped with sequences of genotype 1, but did not group clearly with any subtype described so far. An analysis of partial NS5B gene sequences with additional sequences of African origin also failed to find close similarities between the new sequence and any previously known isolate. Genetic divergence of the coding region of this new sequence with respect to the recognized subtypes of HCV-1 ranged from 20 to 22%. It is proposed that this isolate is a representative of a new, distinct variant of HCV subtype 1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690936     DOI: 10.1099/vir.0.81666-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Cellular immune response to infection by different genotypes of hepatitis C virus.

Authors:  Mohamed El-Shahat Ebeid; Kadry Abdel-Kader El-Bakry
Journal:  Indian J Clin Biochem       Date:  2009-09-16

2.  Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain.

Authors:  Pablo Rivas; María D Herrero; Eva Poveda; Antonio Madejón; Ana Treviño; Maite Gutiérrez; Concepción Ladrón de Guevara; Mar Lago; Carmen de Mendoza; Vincent Soriano; Sabino Puente
Journal:  Am J Trop Med Hyg       Date:  2013-01-21       Impact factor: 2.345

3.  Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo.

Authors:  José M Cuevas; Fernando González-Candelas; Andrés Moya; Rafael Sanjuán
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

4.  Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa.

Authors:  Joseph C Forbi; Michael A Purdy; David S Campo; Gilberto Vaughan; Zoya E Dimitrova; Lilia M Ganova-Raeva; Guo-Liang Xia; Yury E Khudyakov
Journal:  J Gen Virol       Date:  2012-03-28       Impact factor: 3.891

Review 5.  Recombination in hepatitis C virus.

Authors:  Fernando González-Candelas; F Xavier López-Labrador; María Alma Bracho
Journal:  Viruses       Date:  2011-10-24       Impact factor: 5.048

6.  Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource.

Authors:  Donald B Smith; Jens Bukh; Carla Kuiken; A Scott Muerhoff; Charles M Rice; Jack T Stapleton; Peter Simmonds
Journal:  Hepatology       Date:  2014-01       Impact factor: 17.425

7.  A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences.

Authors:  Luiz Carlos Junior Alcantara; Sharon Cassol; Pieter Libin; Koen Deforche; Oliver G Pybus; Marc Van Ranst; Bernardo Galvão-Castro; Anne-Mieke Vandamme; Tulio de Oliveira
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

8.  Evidence of recombination in Hepatitis C Virus populations infecting a hemophiliac patient.

Authors:  Pilar Moreno; Macarena Alvarez; Lilia López; Gonzalo Moratorio; Didier Casane; Matías Castells; Silvia Castro; Juan Cristina; Rodney Colina
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

9.  Complete genome of a European hepatitis C virus subtype 1g isolate: phylogenetic and genetic analyses.

Authors:  Maria A Bracho; Verónica Saludes; Elisa Martró; Ana Bargalló; Fernando González-Candelas; Vicent Ausina
Journal:  Virol J       Date:  2008-06-05       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.